To assess the relative effectiveness of chemotherapy-ICI and ICI-ICI in treating advanced non-squamous NSCLC with PD-L1 expression ≥ 50%, head-to-head clinical trials represent the most informative approach, providing valuable insights for clinical decision-making. The gene discussed is CD274; the disease is non-small cell lung carcinoma.